About a year after its deal for the compound ended with Bayer AG, Paratek Pharmaceuticals Inc. entered a license and development deal with Merck & Co. Inc. worth up to $127 million plus royalties if the FDA approves PTK 0796, a broad-spectrum antibiotic with oral and intravenous versions in Phase I clinical trials. (BioWorld Today) Read More